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New precompetitive ways of working in the pharmaceutical industry are driving the development of
new informatics systems to enable their execution and management. The European Lead Factory (ELF) is
a precompetitive, 30-partner collaboration between academic groups, small–medium enterprises and
pharmaceutical companies created to discover small molecule hits against novel biological targets. A
unique HTS screening and triage workflow has been developed to balance the intellectual property and
scientific requirements of all the partners. Here, we describe the ELF Honest Data Broker, a cloud-based
informatics system providing the scientific triage tools, fine-grained permissions and management tools
required to implement the workflow.Introduction
The European Lead Factory (ELF) [1] is an Innovative Medicines
Initiative (IMI) public–private partnership created to bring phar-
maceutical companies, small–medium enterprises (SMEs) and ac-
ademic laboratories together and stimulate precompetitive drug
discovery. The ELF has built an HTS library [the Joint European
Compound Library (JECL)] [2] from subsets contributed by the
participating pharmaceutical industry partners and through on-
going synthesis within the ELF consortium [3]. This library is
available to academic groups and SMEs across Europe via the
ELF screening, characterisation and medicinal chemistry infra-
structure at the European Screening Centre. The goal of the
academic and SME screening campaign is to discover high-quality,
well-validated small molecules against novel biological targets
that can serve as tool compounds to validate targets or directly
form the foundation of a drug discovery project. The entire
screening library is also distributed to the seven pharma compa-
nies who contributed compounds to the ELF. This enables theCorresponding author:. Pannifer, A.D. (a.pannifer@dundee.ac.uk)
1359-6446/ 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-N
http://dx.doi.org/10.1016/j.drudis.2015.11.005 companies to screen their own internal programmes against a
diverse mid-sized HTS collection far larger than the subsets they
contributed and gives access to chemical space unrepresented in
their own libraries.
A key consideration in creating the ELF was an intellectual
property (IP) model that balances and safeguards the interests
of all the parties concerned and enables sustainable partnership.
Organisations proposing their biological target for screening (pro-
gramme owners) require confidentiality for academic or business
reasons. Organisations contributing compounds (compound own-
ers) might not want all of the compound structures available for
immediate general inspection or analysis because they represent a
considerable body of IP. It is also crucial that the hit molecules and
SAR emerging from the screening process remain confidential to
each programme to enable future development. Conversely,
enough information must be made available to scientists carrying
out the triage to execute a high-quality compound selection and
quality control of screened compounds. To achieve this balance, a
workflow has been created that regulates access to compound
structures and data using a set of fine-grained permissions andC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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FIGURE 1
The European Lead Factory (ELF) triage process. The Joint European Compound Library (JECL) is screened against each target and triaged to a final output of up to
50 compounds. During the triage process, a number of formal stage gates are passed [screening result list (SRL), preliminary hit list (PHL), revised hit list (RHL),
qualified hit list (QHL) and improved hit list (IHL)] and access to compound structures is controlled depending on a triage team member’s permissions [programme
team (PT) or programme clearance team (PCT)] and the stage gate. All data stay entirely within the workflow with very little export permitted until release of the
final 50 compounds at the end of the process. The only exceptions to this rule are compound ID export for reordering and physicochemical property export to
enable LC–MS analysis of up to 100 selected compounds. Monoisotopic mass is required for interpretation of the spectrum, aromatic ring count can assist in cases
where there is no UV signal and log P can help identify compounds that are not flying in the spectrometer. Even here, no structures are released. Parts of the triage
process where structures are blinded are shaded blue and those parts where the structures are visible are shaded pink.
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glossary of acronyms is provided in Box 1. The entire JECL is
screened against each target at a single point to generate the
screening result list (SRL). Hits in the SRL are selected by members
of the programme team (PT) and confirmed at single point based
on biological activity and up to 1% of the SRL can be reordered for
further biological characterisation, such as EC50 measurement. At
this stage, no compound structures are visible; the PT is responsi-
ble for triaging the hundreds or thousands of hits to a maximum ofBOX 1
Glossary of acronyms used in the European Lead Factory
ELF: European Lead Factory.
HDB: Honest Data Broker.
IHL: improved hit list – compounds resulting from the medicinal
chemistry programme to develop selected QHL compounds.
PCT: programme clearance team – group or person responsible for
triage from PHL to QHL.
PHL: preliminary hit list – 0.1% of the SRL selected for visualisation
of structures.
PO: programme owner – the group proposing the biological target
for screening.
PT: programme team – group responsible for initial stage of triage
up to PHL stage.
QHL: qualified hit list 50 compounds for release to programme
owner.
RHL: revised hit list 55 compounds sent for IP check.
SRL: screening result list – HTS output (300 000+ compounds).
98 www.drugdiscoverytoday.com0.1% of the number of compounds on the SRL using an array of
cheminformatic tools and biological data. Once the list of up to
0.1% of the SRL is created, these compounds are registered as the
preliminary hit list (PHL) and responsibility for the triage passes to
the programme clearance team (PCT). For public programmes, the
PCT consists of a small team of medicinal chemists within the ELF,
whereas for programmes belonging to the seven pharmaceutical
companies each has appointed an expert delegate to carry out this
role. At this point, structures of the PHL compounds are unblinded
and the PCT selects up to 55 compounds to create the revised hit
list (RHL). This process enables the JECL to remain largely confi-
dential with only a small number of structures revealed in any
programme. These RHL compounds are subject to a final check for
IP entanglement by the compound owner through the compound
clearance request (CCR) system. The compound owner has no
information about the biological target or the programme owner
when making this check. Once the IP check is cleared, compounds
are then registered on the qualified hit list (QHL) and can be
released to the programme owner. For public programmes, there
is an opportunity to access further characterisation, medicinal
chemistry and modelling capabilities at the ELF to validate and
improve the QHL hits further and generate an improved hit list
(IHL). The selection of compounds at the PHL, RHL and QHL
stages is irreversible in order to eliminate the possibility of PCTs
accessing more than the agreed number of structures.
The complex system of rules governing access to compound
structures, requirements for IP checks, auditing requirements and
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FIGURE 2
A summary of the functionality in the Honest Data Broker (HDB). The
application supports the full workflow of the European Lead Factory (ELF),
providing the triage tools to enable scientists to select the right compounds
while applying the rules of the workflow to safeguard intellectual property.
Project management tools are also provided together with auditing
capability to track the destinations of compounds.
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pound visibility rules created a unique cheminformatics chal-
lenge. This has driven the development of a new application to
support the entire process: the ELF Honest Data Broker (HDB). The
HDB application is hosted on the BIOVIA ScienceCloud platform
and provides four key capabilities: (i) fine-grained permissions to
support the workflow rules; (ii) security features to maintain
confidence in IP protection amongst all the ELF partners; (iii)
scientific tools to execute a high-quality HTS triage; and (iv) tools
to manage and audit programmes. The functionality of the HDB is
summarised in Fig. 2. The ScienceCloud platform was chosen to
host the HDB for a number of reasons. A cloud-based solution
simplifies deployment and maintenance, ScienceCloud has the
high level of security and availability required by the project, it is
based on the Pipeline Pilot1 platform which provides extensive
flexibility in customising the system with the required permissions
and additional triage tools, the pharmaceutical industry partners
were all users of Pipeline Pilot1 and familiar with the chemistry
tools and there is access to the growing set of other applications
hosted on ScienceCloud.
Permissions
The rules governing access to the different IP-related objects and
information are a key aspect of the ELF workflow. Compound
structures and ownership information are controlled to restrict
access to structural knowledge and to ensure that compound
selection is made independently of the origin of the compound,
thus protecting the IP of the compound owners. To address all
these aspects, a system of fine-grained permissions has been creat-
ed. All members of a team associated with a programme are
assigned either a PT or PCT role. PT members are responsible
for initial triaging of the SRL. This is done without access tostructures and requires a suite of cheminformatic tools to enable
an effective compound selection. PCT members can see the struc-
tures of compounds registered on the PHL to provide a ‘chemist’s
eye’ check on selected compounds and are able to order com-
pounds for quality assurance (QA) analysis. Compound origin
remains hidden throughout the process by a double anonymisa-
tion of the compound ID and of the compound owner, this
information only being disclosed when compounds on the QHL
are released to the programme owners.
In addition to the roles associated with a target programme,
further roles are defined to enable execution of the triage process.
The CCR permission is held by compound owners and enables a
member of this group to see compounds sent to them through the
CCR system and clear compounds without IP entanglement.
Clearing compounds is performed without knowledge of either
the target being screened or the identity of the programme owner.
To avoid conflict of interest on targets, compound owners have the
ability to prevent their compounds from being screened on a
particular target. Other permissions are dedicated to the manage-
ment of the compound libraries and to maintain the integrity of
the overall process. The logistics role is assigned to scientists
operating the compound store and allows access to lists of com-
pounds ordered by PT or PCT members. The administrator role is
held by a small number of people in the ELF and they are not
associated with any programme. This role allows programme
setup, supervision, tracking and auditing of information held
within the HDB.
Security
The HDB provides all necessary security levels related to data
storage and authentication. Data are securely stored and processed
in an isolated Oracle1 database located in a private cloud. All data
in transit are secured with SSL/HTTPS with 2048 bit extended
validation certificates; and backups and offline data are encrypted.
For data access, the fine-grained data security model allows a role-
based access-right definition to the different types of data. High
availability of the system is reinforced by the disaster recovery dual
instance of ScienceCloud and the HDB.
Triage tools
The requirement that data and compound structure information
cannot be exported from the HDB during the triage process
requires an effective suite of tools within the system to perform
compound selection. Furthermore, the structure-blinded first
stages of the process put particular emphasis on cheminformatic
tools to allow optimal selection of a few hundred compounds for
the PHL from over 300 000 on the SRL. Some key triage tools are
listed in Table 1. A principal aim of these tools is to allow PT
members to classify compounds by chemical similarity or scaffold
to sample the diversity of hit series fully on the SRL and progress
attractive series to the PHL. Avoidance of simple potency-based
selection in which the PHL might be dominated by a few series and
exclude interesting but slightly less-potent series is crucial [4]. All
compounds in the HDB are assigned a Murcko scaffold ID [5] and a
second scaffold ID based on the ScaffoldTree algorithm [6],
adapted at UCB. This groups molecules by the first two-ring
scaffold found in the iterative ScaffoldTree trimming process, or
by the smallest scaffold if no two-ring scaffold is found. Thesewww.drugdiscoverytoday.com 99
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TABLE 1
Key triage tools in the Honest Data Broker (HDB). Emphasis is placed on understanding the similarity relationships between compounds
when structures are not visible in the early stages of the triage. Deriving knowledge from data deposited in the HDB to inform triage is
also made possible and is an area under active development
Triage tool Function
Property calculators (log P, MW, TPSA, etc.) Generation of key drug-likeness properties
Scaffold clustering Group molecules by core structure
On-the-fly clustering FCFP6/Tanimoto clustering of arbitrary compound lists
Filtering Filter by range, top N, outlier filtering
Activity model calculation False-negative rescue and/or unusual hit identification
Pre-computed ChEMBL activity models Off-target biological activity identification
Ligand efficiency, LLE Size and log P normalised activity estimation
List logic AND/NOT/OR/XOR joining of compound lists
Limited substructure filtering (De)select compounds with structural feature
Binned similarity search Identify compounds similar to query molecule
Pareto/Derringer desirability scoring ‘Soft’ selection of compounds without hard filter limits
Basic math and statistics User-specified mathematical operations
Cross-programme information Shows activity of compounds to against enzyme/receptor classes to facilitate selectivity estimation
CNS filter Desirability model to identify probable CNS-penetrant compounds
SMARTS filtering Substructures encoding structural alerts to identify potentially undesirable features
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compounds based on the core of the molecule. Clustering of
arbitrary user-selected lists of compounds (on-the-fly clustering)
is available using FCFP6 fingerprints/Tanimoto similarity in the
standard clustering component of Pipeline Pilot1 [7,8]. These
methods provide different views on the relationships between
compounds and facilitate grouping in chemical series. The chemi-
cal space around each compound has been analysed and the
number of near neighbours for each compound in the SRL is
reported enabling the triage scientist to look for SAR and poten-
tially prioritise compounds in clusters over singletons. The HDB
can also return compounds similar to a set of query compounds in
a single operation. This is useful if, for example, the screen returns
a relatively small number of hits and the triage team want to select
the near neighbours of each one for visualisation on the PHL and
SAR analysis. Rapid deselection of undesirable compounds is also
possible. Each company and the European Screening Centre have
uploaded a standard set of SMARTS strings [9] identifying unde-
sirable structural features, such as Michael acceptors in molecules.
PT and PCT members can see how many queries are matched in
their own set and in other sets to get a consensus view if required.
In addition, lists of up to 20 substructures, each of up to ten heavy
atoms, can be uploaded allowing selection or deselection of com-
pounds on a project-specific basis. This allows, for example, a PT
member to deselect chemotypes already well explored and prevent
valuable PHL slots being used. Imported structures can also be used
in similarity searches for selection of compounds and, in this case,
there is no limit on the number of heavy atoms in the query
molecules. Measures have been put in place to prevent abuse of
such functionality. In principle, a user could import a large num-
ber of structures and filter the entire SRL to identify JECL com-
pounds with a similarity of 1. This would reveal compounds
identical to, or very similar to, known structures. To prevent this100 www.drugdiscoverytoday.comkind of ‘fishing’ the similarity results are binned in 0.1 Tanimoto
similarity ranges. This retains the usefulness as a triage tool while
obscuring identical, or very nearly identical, relationships between
compounds.
Sophisticated analysis protocols can quickly be created with the
available tools. Compounds can be grouped and analysed by
cluster to generate an immediate overview of the potential of each
cluster to be developed further. Laplacian-modified naive Bayesian
classifiers (Bayesian models) [10] can be built using the HTS data.
The model predictions can, for example, be used to identify
possible false-negatives in the HTS screen and also identify unusu-
al hits in the screen that are likely to be particularly interesting,
atypical chemotypes or false-positives. It is also possible to import
Bayesian models built outside the HDB and use these to rank
compounds. External bioactivity data can also be accessed using
a panel of Bayesian models already built using data from ChEMBL
[11]. Over 1000 models are available and these can also be used to
guide decision making against these targets. The Pareto and Der-
ringer desirability tools [12] allow compounds to be selected
without setting hard cutoffs on property values. This has proved
useful in selecting central nervous system (CNS)-penetrant com-
pounds where one property being close to an ideal value can
compensate for another being outside the conventionally accept-
able range.
A feature of performing a screen within the ELF environment is
the ability to use knowledge from all the accumulated data within
the ELF to inform decisions. Targets assayed in the ELF are given a
high level classification (e.g. Ser/Thr kinase, protease) and the
number of times a compound has shown activity to each class
in all ELF programmes can be displayed. This allows the triage
scientist to get an idea of the selectivity of the compound but
without compromising confidentiality in these other pro-
grammes. The assay technology is also registered in the HDB at
Drug Discovery Today  Volume 21, Number 1  January 2016 REVIEWS
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FIGURE 3
An example of a visualisation from a triage. Compounds are grouped by cluster (x axis) and the scatter of EC50 values (micromolar values on y axis) within each
cluster is demonstrated in a boxplot. It is immediately apparent that cluster 7a has few potent molecules and this can be used to inform decision making.
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active in a given assay design across all programmes can also be
shown. This identifies potential assay-interfering compounds for
further investigation.
Combining all these tools can generate complex protocols that
can be saved as a template for future use. Analysis and visualisation
of the protocol outputs is crucial and a sortable spreadsheet for
analysing the output of a triage is available and more sophisticated
visualisation and spreadsheeting is available through the Pipette
application on ScienceCloud. Pipette has been closely integrated
with the HDB to enable seamless transfer of information between
the HDB and Pipette, always in compliance with business rules. An
example of this visualisation is shown in Fig. 3 where compounds
are grouped by cluster and the range of bioactivity is displayed in a
box-and-whisker plot.
Programme organisation
Programmes are created within the HDB by consortium members
with administrator rights. Mandatory input information such as
Uniprot ID followed by automatic comparison with existing pro-
grammes prevents the same target being screened twice. Key
information such as the programme owner and target class are
also entered here. Target class information is required for func-
tionality such as cross-programme information. Once pro-
grammes are running, two specific challenges are presented by
the ELF. Firstly, the number of programmes running concurrently
within the public screening centre is large and PT and PCT mem-
bers need to deal with a large amount of confidential information.
Permissions prevent data and compound selections being visible
across programmes, whereas the entirely self-contained triageprocess within the HDB eliminates the risk of misdirected emails
and spreadsheets being sent to the wrong programme owner. The
HDB also enables a high level of data organisation within each
programme. Biological assays are accessible through a hierarchical
tree and arbitrary compound worklists can be saved, time-stamped
and annotated for future use. Secondly, PT and PCT members on a
project are often located at different sites and the cloud-based
nature of the HDB enables cross-site project decision-making by
sharing these worklists.
In addition to supporting scientists working directly on the
programme, all interactions between the different roles involved
in a target programme are supported by the HDB application. For
example, the CCR process requires actions from three different
roles: PCT members, who create those requests, compound own-
ers, who need to review and approve or reject the requests, and
administrators, who are in charge of the consistency of the process.
The HDB application provides all necessary features to support the
workflow execution. Events such as creation of CCRs by PCT
members are automatically generated on registering the RHL
and the sending of reminders to compound owners to process
requests are automated, preventing unnecessary manual actions.
Dashboards and reports are available to compound owners and
administrators enabling them to survey which requests are out-
standing and require attention as well as allowing audits and
review over time.
Concluding remarks
The HDB addresses the growing trend in pharmaceutical discovery
for precompetitive partnerships [13] and allows a highly hetero-
geneous group of organisations comprising big pharma, SMEs andwww.drugdiscoverytoday.com 101
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ronment. A unique set of roles and fine-grained permissions meets
the requirements for IP security; and a suite of cheminformatic
tools specifically adapted for the unique workflow enables scien-
tists to carry out a high-quality triage within the rules of the ELF.
The cloud deployment of the HDB supports rapid introduction of
new features in response to user need and defect repair. It also
ensures uniformity of tools and application of the consortium’s
rules rigorously across all partner organisations; an important
consideration in such a widely distributed consortium. This ap-
proach provides a model for similar large-scale public–private
initiatives in the future and is readily adapted for different circum-
stances.102 www.drugdiscoverytoday.comConflicts of interest
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